ADRB2 rs1042713: Understanding Your Beta-2 Receptor Variant
The rs1042713 variant is a common genetic change located in the ADRB2 gene, which provides instructions for making the beta-2 adrenergic receptor. This variant is frequently studied in pharmacogenomics due to its potential association with how individuals respond to beta-agonist medications, such as those used for asthma treatment.
What each genotype means
Increased asthma medication sensitivity
This genotype, often referred to as the Arg16 homozygous state, has been associated in some studies with a stronger initial response to short-acting beta-agonist asthma medications. However, research also suggests that individuals with this genotype may experience a greater decrease in medication effectiveness over time with regular use. Please discuss your asthma management plan and medication dosing with your clinician or pharmacist.
This genotype is relatively common, with allele frequencies for the A and G variants typically ranging between 0.4 and 0.6 across many global populations.
Intermediate asthma medication response
This heterozygous genotype represents a mix of the Arg16 and Gly16 forms of the beta-2 adrenergic receptor. Studies on how this specific combination influences the long-term effectiveness of asthma inhalers have shown mixed results, and clinical responses can vary significantly between individuals. Please consult your healthcare provider or pharmacist regarding your specific medication response and treatment strategy.
This is a common genotype found frequently across diverse ancestral groups.
Stable asthma medication response
This genotype, often referred to as the Gly16 homozygous state, is the most common form in many populations and has been associated with more stable responses to regular beta-agonist use compared to the Arg16 variant. While some research suggests this genotype may show less change in effectiveness over time, individual responses to asthma therapy are complex. Always discuss your treatment and any concerns about medication efficacy with your clinician or pharmacist.
This is a common genotype, with the G allele being the most prevalent form of this variant in most populations worldwide.
What is the rs1042713 Variant?
The rs1042713 variant is a single nucleotide polymorphism (SNP) found within the ADRB2 gene, which is located on chromosome 5. In scientific literature, this variant is often referred to as the Arg16Gly polymorphism because it results in an amino acid substitution at position 16 of the beta-2 adrenergic receptor protein. Specifically, the A allele encodes the amino acid arginine, while the G allele encodes glycine. Because this change occurs in the coding region of the gene, it has the potential to alter the structure or function of the resulting receptor protein. Researchers track this specific location to understand how minor variations in our genetic code can lead to differences in physiological responses to external stimuli, including medications that target this receptor system.
The Role of the ADRB2 Gene
The ADRB2 gene encodes the beta-2 adrenergic receptor, a protein found on the surface of many cell types, including those in the smooth muscle of the airways. This receptor is a critical component of the sympathetic nervous system, mediating the body's response to adrenaline and noradrenaline. When these signaling molecules bind to the receptor, they trigger a cascade of events that typically lead to the relaxation of bronchial smooth muscle, which helps open the airways. Because of this function, the ADRB2 gene is a primary target for bronchodilator medications used to manage asthma and other respiratory conditions. Variations in this gene are of significant interest to scientists because they may influence how effectively these receptors respond to both natural hormones and synthetic drugs.
Research and Clinical Associations
Research into rs1042713 has primarily focused on its role in pharmacogenomics, particularly regarding the efficacy of inhaled beta-agonist medications like salbutamol. Some studies have observed that individuals with different genotypes may show variations in their bronchodilator response, with certain alleles potentially linked to better or worse lung function improvement after treatment. Additionally, some research has explored associations between this variant and other physiological traits, such as blood pressure regulation or metabolic responses, though evidence in these areas is often mixed or context-dependent. It is important to note that the evidence strength for these associations is considered moderate. Genetic factors are only one piece of a complex puzzle that includes environmental triggers, disease severity, and other biological variables. Consequently, this variant is not used as a standalone diagnostic tool for clinical decision-making.
Understanding Your Results
If you have information about your rs1042713 genotype, it is essential to interpret it within the context of your overall health and medical history. While genetic research provides valuable insights into population-level trends, it cannot predict an individual's specific clinical outcome. Many factors beyond genetics influence how a person responds to medication, including age, lifestyle, and the presence of other health conditions. You should never use genetic information to make changes to your prescribed treatment plan or medication dosage. If you are curious about how your genetic profile might relate to your asthma management or other health concerns, please discuss this information with your clinician or pharmacist. They are the best resources to help you understand how to integrate this knowledge into your personalized healthcare strategy.
How common is this variant?
The rs1042713 variant is common across global populations, with the G allele generally being more frequent than the A allele in many groups, though frequencies vary significantly by ancestry.
Frequently asked questions
Does my rs1042713 genotype mean my asthma medication won't work?
No, having a specific genotype does not mean your medication will not work. Genetic variants are only one of many factors that influence drug response, and most people with asthma find effective treatment regardless of their genotype.
Should I change my asthma inhaler based on this SNP?
Absolutely not. You should never change your medication or dosage based on genetic test results without consulting your doctor. Always follow the treatment plan prescribed by your healthcare provider.
Is rs1042713 a diagnostic test for asthma?
No, rs1042713 is not a diagnostic test for asthma. Asthma is a complex condition diagnosed by clinicians based on symptoms, physical exams, and lung function tests, not by genetic testing alone.
Where can I find more information about ADRB2?
You can find reliable information about the ADRB2 gene and its functions through resources like MedlinePlus Genetics or the GeneCards database. These sites provide comprehensive summaries of gene function and associated research.
Sources & further reading
Educational information only, last refreshed 10/1/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1042713?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADRB2
Variant in the beta-2 adrenergic receptor linked to metabolic regulation, exercise-induced lipolysis, and endurance performance.
Synonymous polymorphism in the beta-2 adrenergic receptor (Gln27Glu) modulating receptor down-regulation.
The Gln27Glu variant in the beta-2 adrenergic receptor is associated with metabolic and vascular responses to exercise.
Modulates beta-2 adrenergic receptor expression and cardiovascular reactivity.
This variant in the beta-2 adrenergic receptor gene is associated with differential responses to beta-agonist therapy in asthma patients.
Functional variant in the beta-2 adrenergic receptor linked to metabolic rate and cardiovascular reactivity.